[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atheroscleroses-cerebral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atheroscleroses-cerebral":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,64,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100308157","morphology-of-advanced-symptomatic-cerebral-plaques-with-high-embolic-potential-100308157",false,"NCT03291652","Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential","Inclusion Criteria:\n\n* Inclusion Criteria for the Symptomatic Group:\n\n  1. Patient is 30 to 85 years of age, inclusive.\n  2. Patients who have an acute infarct in diffusion-weighted MRI compatible with artery-to-artery thrombo-embolism, a relevant intracranial atherosclerotic stenosis ≥60%, and MES detected by TCD.\n  3. Patient who has no contra-indication for the proposed imaging tests.\n  4. Patient understands the purpose and requirements of the study, and has provided an informed consent.\n* Inclusion Criteria for the Asymptomatic Group:\n\n  1. Patient is 30 to 85 years of age, inclusive.\n  2. Patient who has a high-grade (\\>60%) intracranial stenosis (signal void in MR angiography) but without infarct in the corresponding vascular territory in DWI or T2-weighted sequence.\n  3. Patient has no MES detected on TCD examination.\n  4. Patient who has no contra-indication for the proposed imaging tests.\n  5. Patient understands the purpose and requirements of the study, and has provided an informed consent.\n\nExclusion Criteria:\n\nSubject who meets one or more of the following criteria cannot be recruited in the study:\n\n1. Stroke etiology uncertain or unrelated to intracranial atherosclerosis, such as cardioembolism, Moyamoya disease, small vessel disease, etc.\n2. A tandem stenosis \\>50% at proximal internal carotid artery.\n3. Bleeding propensity: active peptic ulcer disease, major systemic hemorrhage within 30 days, thrombocytopenia (platelets \\\u003C100 x 109\u002FL), coagulopathy (INR \\>1.5).\n4. A medical condition that would not allow the patient to adhere to the protocol or complete the study.","ALL","30 Years","85 Years",{"count":19,"type":20},140,"ESTIMATED","OBSERVATIONAL","The study is to attain early recognition of the unstable plaques which have an imminent embolic risk in patients with intracranial atherosclerotic disease (IAD).",[24,25],"Ischemic Stroke","Atheroscleroses, Cerebral",[24,27,28,29],"atherosclerosis","Plaque morphology","DSA\u002F3DRA","RECRUITING","2026-02-21",{"date":33,"type":34},"2026-02-24","ACTUAL",{"date":36,"type":34},"2010-02",{"date":38,"type":20},"2027-12-31",{"name":40,"class":41},"Chinese University of Hong Kong","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":42},"100308474","morphologic-evolution-and-remodeling-of-intracranial-atherosclerosis-a-longitudinal-study-by-3d-rotational-angiography-100308474","NCT03295773","Morphologic Evolution and Remodeling of Intracranial Atherosclerosis: A Longitudinal Study by 3D-rotational Angiography","Inclusion Criteria:\n\n1. Patient is 30 to 85 years of age, inclusive.\n2. Patients who have an acute infarct in diffusion-weighted MRI compatible with artery-to-artery thrombo-embolism and a relevant intracranial atherosclerotic stenosis ≥60%.\n3. Patient who has no contra-indication for the proposed imaging tests.\n4. Patient understands the purpose and requirements of the study, and has provided an informed consent.\n\nExclusion Criteria:\n\nPatient with any of the following conditions would be excluded:\n\n1. Stroke etiology uncertain or unrelated to intracranial atherosclerosis, such as cardioembolism, Moyamoya disease, small vessel disease or primary angiitis of CNS.\n2. A tandem stenosis \\>50% at extra-cranial internal carotid artery.\n3. Bleeding propensity: active peptic ulcer disease, major systemic hemorrhage within 30 days, thrombocytopenia (platelets \\\u003C100 x 109\u002FL), coagulopathy (INR \\>1.5).\n4. A medical condition that would not allow the patient to adhere to the protocol or complete the study.","18 Years","80 Years",{"count":19,"type":20},"This study is to elucidate the morphologic evolution and remodeling of ICAD under stringent control of cardiovascular risk factors.",[24,25],[24,55,56,57],"3D-rotational angiography","Morphology","Atherosclerosis",{"date":33,"type":34},{"date":60,"type":34},"2016-08-22",{"date":62,"type":20},"2027-06-30",{"name":40,"class":41},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":42},"100572831","digital-secondary-prevention-after-atherosclerotic-cardiovascular-disease-100572831","NCT06738381","Digital Secondary Prevention After Atherosclerotic Cardiovascular Disease","Individually Tailored Digital Secondary Prevention After Hospitalization for Atherosclerotic Cardiovascular Disease: a Randomized Proof-of-concept Study","Inclusion criteria (all the following):\n\n* Aged \\>=18 years and signed informed consent and expected cooperation according to ICH\u002FGCP and national\u002Flocal regulations\n* Hospitalised with an planned or unplanned ASCVD event and\u002For established atherosclerosis\n* Access to a smartphone or tablet\n\nExclusion criteria (any of the following):\n\n-Any condition or situation, that in the investigator's opinion could put the subject at significant risk, confound the study results, interfere significantly with the subject participation in the study, or rendering informed consent unfeasible not limited to: cognitive impairment, seizure disorders, active suicidal intent or plans, substance or alcohol dependence, psychotic disease, major depressive disorders or bipolar disorders, receiving concurrent psychological treatments, and ongoing night shift work.\n\n* Short life expectancy (\\\u003C12 months) due to end-organ (i.e COPD 4, CKD 4\u002F5) or malignant diseases\n* Clinically significant symptoms of anxiety and depression (HADS A and\u002For HADS-D score ≥8)\n* Not being able to understand Norwegian.",{"count":72,"type":20},300,"INTERVENTIONAL",[75],"NA","Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide and in Norway. Approximately 50% of the patients admitted to hospitals with an acute ASCVD event has had a previous event. The high number of patients being readmitted to hospitals with new ASCVD events is to a large degree explained by poor control of established risk factors such as high LDL-cholesterol, high blood pressure (BP), diabetes, obesity, smoking, and lack of physical activity, as well as poor adherence to evidence-based medication. This pragmatic, open-label proof-of-concept study conducted at three secondary care hospitals will randomly assign patients hospitalized with an ASCVD event to either: (i) brief advice, tailored discharge information to general practitioners, and a nurse-led outpatient visit (control), or (ii) the same interventions as (i) plus a single in-hospital motivational counselling session and access to a digital platform for a 6 months period with patient information\u002Fvideos and an individualized treatment plan and follow-up plan. The primary end point will be between-group differences in the proportion who report having attended follow-up visits in primary (primary care physicians and community-based healthy life centres) and specialist (cardiac rehabilitation programs, hospital outpatient visits) healthcare after 8 weeks and 6 months follow-up. Secondary end points will be change in the SMART2 risk score and cardiovascular risk factors between baseline and 6 and 12 months follow-up. Exploratory end points will be changes in adherence to cardiovascular drugs, self-care behaviour, health literacy, patient activation, and quality of life.",[78,25,79],"Atheroscleroses, Coronary","Atherosclerotic Ischemic Disease","2025-02-19",{"date":82,"type":34},"2025-02-21",{"date":84,"type":34},"2025-02-03",{"date":86,"type":20},"2026-12-20",{"name":88,"class":41},"Vestre Viken Hospital Trust",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":96,"targetDuration":98,"studyType":21,"phases":4,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100563346","balloon-expandable-des-for-icas-registry-study-bdes-icas-registry-100563346","NCT06614972","Balloon-expandable DES for ICAS Registry Study (BDES-ICAS Registry)","Clinical Outcome of Balloon-Expandable Drug-Eluting Stenting For Patients With Intracranial Atherosclerotic Stenosis: a Prospective, Multicenter, Real-World Registry Study","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. According to clinical and angiographic evidence, symptomatic intracranial arteries stenosis within 3 months include vertebral artery V4 segment or internal carotid artery C2-C7 segment, and the degree of diseased arterial stenosis is between 70%\\~99% (WASID method).\n3. Patients have more than 1 episode of symptoms including stroke or transient ischemia attack (TIA) after intensive medical treatment (including antiplatelet therapy, antihypertensive, hypoglycemic and lipid-lowering treatments).\n4. Patients have at least 1 risk factor for intracranial atherosclerosis, including previous or existing hypertension, hyperlipidemia, diabetes mellitus, smoking, alcohol consumption, obesity, underlying heart disease, family history of atherosclerotic vascular disease, hyperhomocysteinemia and so on.\n5. Baseline mRS score ≤3.\n6. Patient or guardian signs informed consent.\n\nExclusion Criteria:\n\n1. Patients who cannot receive dual antiplatelet therapy due to existing diseases or with server coagulation dysfunction, uncontrolled serious infections, serious systemic diseases, uncontrollable hypertension and other conditions are not suitable for surgery.\n2. Patients with aneurysm that cannot be treated in advance or at the same time or are not suitable for surgery.\n3. Gastrointestinal disease with active bleeding.\n4. Myocardial infarction or massive cerebral infarction within 2 weeks.\n5. Patients with known severe allergies or contraindications to heparin, rapamycin, anesthesia and contrast media.\n6. Life expectancy \\<12 months.\n7. According to the judgement of the investigator, other situations that are not suitable for enrollment.",{"count":97,"type":20},520,"5 Years","To study the clinical outcomes after implantation of balloon-expandable drug-eluting stents in patients with symptomatic intracranial atherosclerotic stenosis in prevention of composite event of any stroke and death within 30 days and ischemic stroke in the territories of the responsible artery from 31 days to 1-year.",[25,101,102],"Intracranial Atherosclerosis","Ischemia Stroke",[104,105],"Intracranial Atherosclerosis Stroke","Drug-eluting stent","NOT_YET_RECRUITING","2024-09-23",{"date":109,"type":34},"2024-09-26",{"date":111,"type":20},"2024-09-30",{"date":113,"type":20},"2030-09-30",{"name":115,"class":41},"RenJi Hospital"]